142 related articles for article (PubMed ID: 8378092)
1. Activation of gene transcription by the amino terminus of the N-Myc protein does not require association with the protein encoded by the retinoblastoma suppressor gene RB1.
Cziepluch C; Wenzel A; Schürmann J; Schwab M
Oncogene; 1993 Oct; 8(10):2833-8. PubMed ID: 8378092
[TBL] [Abstract][Full Text] [Related]
2. The retinoblastoma susceptibility gene product regulates Myc-mediated transcription.
Adnane J; Robbins PD
Oncogene; 1995 Jan; 10(2):381-7. PubMed ID: 7838535
[TBL] [Abstract][Full Text] [Related]
3. v-Myc, but not Max, possesses domains that function in both transcription activation and cellular transformation.
Min S; Taparowsky EJ
Oncogene; 1992 Aug; 7(8):1531-40. PubMed ID: 1630816
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max.
Amati B; Dalton S; Brooks MW; Littlewood TD; Evan GI; Land H
Nature; 1992 Oct; 359(6394):423-6. PubMed ID: 1406955
[TBL] [Abstract][Full Text] [Related]
5. Gene-regulatory properties of Myc helix-loop-helix/leucine zipper mutants: Max-dependent DNA binding and transcriptional activation in yeast correlates with transforming capacity.
Crouch DH; Fisher F; Clark W; Jayaraman PS; Goding CR; Gillespie DA
Oncogene; 1993 Jul; 8(7):1849-55. PubMed ID: 8510929
[TBL] [Abstract][Full Text] [Related]
6. c-Myc does not require max for transcriptional activity in PC-12 cells.
Ribon V; Leff T; Saltiel AR
Mol Cell Neurosci; 1994 Jun; 5(3):277-82. PubMed ID: 8087425
[TBL] [Abstract][Full Text] [Related]
7. YY1 can inhibit c-Myc function through a mechanism requiring DNA binding of YY1 but neither its transactivation domain nor direct interaction with c-Myc.
Austen M; Cerni C; Lüscher-Firzlaff JM; Lüscher B
Oncogene; 1998 Jul; 17(4):511-20. PubMed ID: 9696045
[TBL] [Abstract][Full Text] [Related]
8. Crosstalk between Myc and activating transcription factor 2 (ATF2): Myc prolongs the half-life and induces phosphorylation of ATF2.
Miethe J; Schwartz C; Wottrich K; Wenning D; Klempnauer KH
Oncogene; 2001 Dec; 20(56):8116-24. PubMed ID: 11781825
[TBL] [Abstract][Full Text] [Related]
9. Functional analysis of the N-terminal domain of the Myc oncoprotein.
Oster SK; Mao DY; Kennedy J; Penn LZ
Oncogene; 2003 Apr; 22(13):1998-2010. PubMed ID: 12673205
[TBL] [Abstract][Full Text] [Related]
10. The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation.
Lüscher B; Larsson LG
Oncogene; 1999 May; 18(19):2955-66. PubMed ID: 10378692
[TBL] [Abstract][Full Text] [Related]
11. Mmip1: a novel leucine zipper protein that reverses the suppressive effects of Mad family members on c-myc.
Gupta K; Anand G; Yin X; Grove L; Prochownik EV
Oncogene; 1998 Mar; 16(9):1149-59. PubMed ID: 9528857
[TBL] [Abstract][Full Text] [Related]
12. Functional interaction of the c-Myc transactivation domain with the TATA binding protein: evidence for an induced fit model of transactivation domain folding.
McEwan IJ; Dahlman-Wright K; Ford J; Wright AP
Biochemistry; 1996 Jul; 35(29):9584-93. PubMed ID: 8755740
[TBL] [Abstract][Full Text] [Related]
13. Opposite transcriptional activity between the wild type c-myc gene coding for c-Myc1 and c-Myc2 proteins and c-Myc1 and c-Myc2 separately.
Batsché E; Crémisi C
Oncogene; 1999 Oct; 18(41):5662-71. PubMed ID: 10523846
[TBL] [Abstract][Full Text] [Related]
14. Amino-terminal domains of c-myc and N-myc proteins mediate binding to the retinoblastoma gene product.
Rustgi AK; Dyson N; Bernards R
Nature; 1991 Aug; 352(6335):541-4. PubMed ID: 1865909
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional activation domain of the muscle-specific gene-regulatory protein myf5.
Braun T; Winter B; Bober E; Arnold HH
Nature; 1990 Aug; 346(6285):663-5. PubMed ID: 2385294
[TBL] [Abstract][Full Text] [Related]
16. Low molecular weight inhibitors of Myc-Max interaction and function.
Yin X; Giap C; Lazo JS; Prochownik EV
Oncogene; 2003 Sep; 22(40):6151-9. PubMed ID: 13679853
[TBL] [Abstract][Full Text] [Related]
17. DNA binding by N- and L-Myc proteins.
Ma A; Moroy T; Collum R; Weintraub H; Alt FW; Blackwell TK
Oncogene; 1993 Apr; 8(4):1093-8. PubMed ID: 8455937
[TBL] [Abstract][Full Text] [Related]
18. Mouse Sin3A interacts with and can functionally substitute for the amino-terminal repression of the Myc antagonist Mxi1.
Rao G; Alland L; Guida P; Schreiber-Agus N; Chen K; Chin L; Rochelle JM; Seldin MF; Skoultchi AI; DePinho RA
Oncogene; 1996 Mar; 12(5):1165-72. PubMed ID: 8649810
[TBL] [Abstract][Full Text] [Related]
19. Mutant envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein.
Epinat JC; Kazandjian D; Harkness DD; Petros S; Dave J; White DW; Gilmore TD
Oncogene; 2000 Feb; 19(5):599-607. PubMed ID: 10698504
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional activation by human c-myb and v-myb genes.
Kalkbrenner F; Guehmann S; Moelling K
Oncogene; 1990 May; 5(5):657-61. PubMed ID: 2189102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
